Calviri develops multi-cancer diagnostic tests that utilize a peptide array platform to detect stage 1 cancers with high sensitivity from a small blood sample. The company also offers premade therapeutic and preventative vaccines targeting shared tumor antigens, addressing the need for effective and accessible cancer treatment options.
Funding
$19.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer diagnostic methods often lack the sensitivity to detect tumors at Stage 1, when treatment is most effective. Existing therapies are not always broadly effective or affordable, leaving many patients with limited options. This results in delayed diagnoses and reduced chances of successful treatment, contributing to high mortality rates.
Solution
Calviri is developing a suite of diagnostic and therapeutic products designed to improve cancer detection and treatment outcomes. Their multi-cancer diagnostic tests utilize a peptide array platform to detect cancers at Stage 1 from a small blood sample, addressing the sensitivity limitations of current tests. In addition, Calviri offers premade therapeutic and preventative vaccines targeting shared tumor antigens, eliminating the need for personalized vaccine development. These vaccines aim to treat existing cancers and prevent future development across various cancer types. By focusing on early detection and broadly applicable immunotherapies, Calviri seeks to provide more effective and accessible cancer solutions.
Target Audience
Calviri's products target both human and canine markets, including individuals at risk of developing cancer, those diagnosed with early-stage cancer, and veterinarians seeking advanced diagnostic and preventative tools.
Features
- Multi-cancer diagnostic tests capable of detecting Stage 1 cancers with high sensitivity
- Peptide array platform for analyzing blood samples
- Premade therapeutic vaccines targeting shared tumor antigens for broad applicability
- Preventative vaccines designed to prevent the development of multiple cancer types
- Focus on frameshift neoantigens derived from errors in RNA processing
- Ongoing dog vaccine trial assessing the performance of a preventative cancer vaccine